BriaCell Therapeutics Corp.

NasdaqCM:BCTX Stock Report

Market Cap: US$34.3m

BriaCell Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BCTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders182,6082.1%
Institutions554,1906.37%
Hedge Funds657,5957.56%
General Public7,305,39484%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1183.9%.

Top Shareholders

Top 25 shareholders own 16.03% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.56%
Citadel Advisors LLC
657,595US$2.6m5,850%no data
2.49%
Cable Car Capital LLC
216,821US$854.6k0%0.29%
1.2%
Richard Abbe
104,000US$409.9k0%no data
1.14%
Heights Capital Management, Inc.
98,944US$390.0k0%0.08%
0.85%
Sabby Management, LLC
73,915US$291.4k0%4.25%
0.75%
Iridian Asset Management LLC
65,000US$256.2k0%0.09%
0.64%
Iroquois Capital Management, LLC
56,000US$220.7k0%5.69%
0.4%
William Williams
35,218US$138.8k3,030%no data
0.22%
Giuseppe Del Priore
18,839US$74.3k0%no data
0.17%
LuminArx Capital Management LP
15,000US$59.1k0%0.06%
0.13%
UBS Asset Management AG
11,541US$45.5k1,710%no data
0.11%
Gadi Levin
9,438US$37.2k52,300%no data
0.11%
Miguel Lopez-Lago
9,419US$37.1k0%no data
0.11%
3i Fund
9,170US$36.1k0%0.3%
0.05%
Jeremy Myung Plambeck
4,330US$17.1k0%no data
0.037%
FMR LLC
3,225US$12.7k0%no data
0.035%
Morgan Stanley
3,021US$11.9k-13.7%no data
0.013%
Jamieson Bondarenko
1,132US$4.5k41.7%no data
0.0092%
National Bank Investments Inc.
802US$3.2k0%no data
0.0052%
Fédération des caisses Desjardins du Québec
455US$1.8k-62.2%no data
0.0019%
Vaughn Embro-Pantalony
163US$641.30%no data
0.0011%
Royal Bank of Canada
100US$394.40%no data
0.0011%
Allworth Financial, L.P.
100US$394.40%no data
0.00076%
Jane Gross
66US$260.60%no data
0.00043%
SSA Swiss Advisors AG
37US$147.50%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 13:00
End of Day Share Price 2026/07/10 00:00
Earnings2026/04/30
Annual Earnings2025/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BriaCell Therapeutics Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Ashok KumarThinkEquity LLC